Manager TitleAgeSince
President - 29/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
-0.04%-1.40%+57.16%+108.15% 1,034B
+1.17%+4.76%+56.42%+73.50% 671B
-0.58%+0.80%+22.82%+75.58% 460B
-0.46%-1.00%+28.80%+37.82% 353B
-1.10%+4.98%+25.00%+45.91% 309B
+0.07%+1.61%-0.21%+13.78% 255B
+0.29%+1.63%+56.46%+73.00% 240B
-0.57%+1.51%-16.80%-54.23% 207B
+1.08%+1.59%+33.83%+97.29% 188B
Average -0.13%+1.27%+29.28%+52.31% 412.97B
Weighted average by Cap. -0.43%+1.04%+38.12%+67.65%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock